Clinical Trials Directory

Trials / Conditions / Thromboangiitis Obliterans

Thromboangiitis Obliterans

8 registered clinical trials studyying Thromboangiitis Obliterans — 1 currently recruiting.

StatusTrialSponsorPhase
Enrolling By InvitationFollow-up Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-L)
NCT07023965
Beijing Northland Biotech. Co., Ltd.—
CompletedStudy to Assess the Efficacy and Safety of CLBS12 in Patients with Critical Limb Ischemia (CLI)
NCT02501018
Lisata Therapeutics, Inc.Phase 2
UnknownEffectiveness and Safety of Adipose-Derived Regenerative Cells for the Treatment of Critical Lower Limb Ischem
NCT02864654
Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian FederationPhase 1 / Phase 2
UnknownPurified CD34+ Cells Versus Peripheral Blood Mononuclear Cells in Treatment of Critical Limb Ischemia
NCT02089828
Shanghai Zhongshan HospitalN/A
CompletedContrast Enhanced Ultrasound and Muscle
NCT02128750
University Hospital, GrenobleN/A
CompletedTreatment of Thromboangiitis Obliterans (Buerguer's Disease) With Bosentan
NCT01447550
Hospital Universitario Getafe—
CompletedADDICTAO: Psychological and Addictive Profile of Patients With Buerger's Disease
NCT01064206
University Hospital, Lille—
Approved For MarketingIndividual Patient Expanded Access IND for Selexipag (Uptravi) in Participants With Non-healing Wound, Buerger
NCT04914247
Actelion—